Pharma Giant Makes Deal with a "Drug Smuggler"

You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.   Dear Fellow Investor, A small, under-the-radar biotech company just raised $500 MILLION to combat Alzheimer's, Parkinson's and other brain disorders. They accomplished this thanks to a revolutionary new drug delivery technology that solves one of biotech's oldest problems. You see, getting drugs into the brain is extremely difficult. The blood-brain barrier blocks almost everything. But this company engineered a way to sneak their treatments across the barrier using a "smuggler." With an extra $500 million in funding, they can now accelerate development of medicines targeting Alzheimer's, Parkinson's, and more. Even Big Pharma giant Biogen licensed this biotech's clever delivery system last year. But you'll want to get in before more partnerships emerge... Reveal this game-changing biotech's name and ticker HERE >>> "The Buck Stops Here" Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets Unsubscribe